BofA raised the firm’s price target on Argenx (ARGX) to $887 from $880 and keeps a Buy rating on the shares after the company reported positive results from the Phase 3 SERON study evaluating Vyvgart in AChR- generalized myasthenia gravis patients last week. The firm, which models $6.4B in peak sales in gMG in 2034, notes that gMG now contributes $447 per share to its valuation of Argenx.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Vyvgart Expansion and Pipeline Strength Bolster Buy Rating
- Argenx Se’s Vyvgart Gains Momentum with Successful Phase 3 Results and Market Expansion Potential
- Argenx price target raised to $808 from $795 at Jefferies
- Argenx price target raised to $820 from $750 at Piper Sandler
- Argenx’s Vyvgart Shows Promising Phase III Results, Expanding Market Potential for Seronegative gMG Patients